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Abstract Presently, several pneumococcal proteins are
being evaluated as potential vaccine candidates. Here, we
gather novel insights in the immunogenicity of PLY, PsaA,
PspA, PspC, NanA, Hyl, PpmA, SlrA, Eno, IgA1-protease,
PdBD, BVH-3, SP1003, SP1633, SP1651, SP0189 and
SP0376. We developed a multiplex bead-based immunoassay
(xMAP® Technology, Luminex Corporation) to simulta-
neously quantify antibodies against these 17 pneumococcal
proteins in serum. The median fluorescence intensity
(MFI) values obtained for human pooled serum with the
multiplex assay were between 82% and 111% (median
94%) of those obtained with the singleplex assays. For
IgG, the coefficient of variation (CV) in serum ranged
from 2% to 9%, for IgA, the CV ranged from 3% to 14%
and for IgM, the CV ranged from 11% to 15%. Using
this immunoassay, we showed that anti-pneumococcal
antibody levels exhibited extensive inter-individual variability
in young children suffering from invasive pneumococcal
disease. All proteins, including the proteins with, as yet,
unknown function, were immunogenic. In conclusion, the
multiplex Streptococcus pneumoniae immunoassay based on
proteins is reproducible. This assay can be used to monitor
anti-S. pneumoniae antibody responses in a material- and
time-saving manner.
Introduction
Streptococcus pneumoniae (S. pneumoniae, pneumococcus)
is an important human pathogen that causes life-threatening
diseases such as pneumonia and meningitis, as well as less
serious but highly prevalent diseases such as otitis media
and sinusitis. Between 2002 and 2003, pneumonia
accounted for 19% of the 10.6 million deaths per annum
among children younger than 5 years of age [1]. Ninety
percent of childhood deaths occurred in developing
countries [2], including Bangladesh [3, 4]. The global
incidence of pneumococcal meningitis in children is 17
cases per 100,000. The case–fatality rate (CFR) for
pneumococcal meningitis is high. In 2000, the global
pneumococcal meningitis CFR was 59%, ranging from
29% in the Western Pacific to 73% in Africa [5].
Fortunately, the availability of the 23-valent capsular
polysaccharide and 7-valent pneumococcal conjugate
vaccines (PCV23 and PCV7, respectively) has resulted
in a dramatic reduction in the morbidity and mortality of
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pneumococcal diseases. However, the high costs and still
limited vaccine-mediated protection, which is restricted to the
included serotypes, have prevented its implementation in
large-scale immunisation programmes in developing
countries. For these reasons, there is considerable interest in
designing alternative and more cost-effective strategies.
Presently, several pneumococcal proteins are being evaluated
as potential vaccine candidates. Optimally, these would
provide protection against pneumococcal infection regardless
of serotype [6]. To date, the most promising protein vaccine
candidates include pneumolysin (PLY), pneumococcal
surface adhesin A (PsaA), pneumococcal surface protein A
(PspA) and pneumococcal surface protein C (PspC) [7].
These proteins are produced by virtually all clinical
isolates of the pneumococcus. PLY is a 53-kDa protein
that causes cytolysis, induces complement activation and
the production of cytokines and nitric oxide [8–12]. In
addition, PLY has been assigned several functions with
respect to modification of the immune response. PLY has
recently been shown to interact with Toll-like receptor 4
(TLR-4) [13]. PsaA is a surface-exposed 37-kDa lipopro-
tein that plays a major role in pneumococcal attachment to
the host cell and virulence [14]. PspA is a choline-binding
surface protein which inhibits complement-mediated
phagocytosis, binds to lactoferrin and, as such, prevents
lactoferrin-mediated killing [15]. Antibodies to pneumo-
coccal proteins PspA, PsaA and PLY have been shown to
develop early in life [16, 17]. PspC (also known as CbpA
or SpsA) acts as an adhesin and binds the complement
regulatory protein factor H, to provide resistance to
complement [13, 18].
We developed a multiplex bead-based immunoassay
using Luminex xMAP® Technology to gather novel insights
into the immunogenicity of PLY, PsaA, PspA and PspC
and 13 other pneumococcal proteins. With this assay,
antibodies to these 17 pneumococcal proteins can be
quantified simultaneously. Thus far, for the pneumococ-
cus, this technology was only used for the measurement
of antibodies directed to different pneumococcal capsular
polysaccharides [19–21].
Materials and methods
Antigens
The pneumococcal proteins PLY, PsaA, PspA, PspC,
neuraminidase A (NanA), hyaluronidase (Hyl), putative
proteinase maturation protein A (PpmA), streptococcal
lipoprotein rotamase A (SlrA), α-enolase (Eno), immuno-
globulin A1 protease (IgA1-protease), PdBD and BVH-3,
SP1003, SP1633, SP1651, SP0189, and SP0376 were used.
NanA plays an important role in biofilm formation and
promotes pneumococcal brain endothelial cell invasion [22,
23]. Hyl is present on the majority of strains. The enzyme
degrades essential components of the host’s extracellular
matrix and, as such, it may facilitate bacterial spread in host
tissues [13, 24]. PpmA and SlrA, two surface-exposed
lipoproteins, have been shown to play a role in virulence
and colonisation [25, 26]. Eno has been identified both in
the cytoplasm and on the surface of pneumococci and is
involved in virulence by the activation of plasmin into
plasminogen, a host collagen-degrading enzyme [27].
IgA1-protease plays an important role in pneumococcal
colonisation. IgA1-protease modifies IgA1 antibodies so
that it promotes rather than inhibits pneumococcal
adherence to epithelial cells in a model of colonisation
[28]. PdBD is a mutant version of PLY with less cytolytic
activity and reduced ability to activate complement [29].
BVH-3 is capable of conferring protection against lethal
experimental S. pneumoniae infection. This protein family
was also designated Pht (for pneumococcal histidine triad)
[30, 31]. SP1003, SP1633, SP1651, SP0189 and SP0376
are pneumococcal proteins with currently unknown func-
tions. Recently, a comprehensive review summarising the
surface-exposed virulence factors and their functions was
published [13].
The genes encoding the proteins NanA, PsaA, PspA,
PspC, SP1633, SP1651, SP0189, SP0376, Hyl, PLY and
PpmA were isolated from S. pneumoniae strain TIGR4
chromosomal DNA and cloned in the vector pOPINF
using In-Fusion Technology. Cell extracts were made
from the recombinant Escherichia coli (Rosetta) strains
and the recombinant proteins purified by immobilised
metal affinity chromatography using the poly-His tag
added to the N-terminal end of the protein during the
cloning procedure. The genes used for the production of
the recombinant antigens Eno, SlrA and PpmA were
amplified by polymerase chain reaction (PCR) from S.
pneumoniae D39. IgA1-protease was amplified from S.
pneumoniae TIGR4. The amplified DNA was cloned into
a pET11a expression vector (Stratagene) and electro-
transformed into E. coli BL21(DE3). The expression of
recombinant protein was induced by the addition of
isopropyl-β-D-thio-galactoside (IPTG) and the recombi-
nant proteins were purified by Ni+ affinity chromatogra-
phy, as described previously [16, 25, 32]. The genes
encoding BVH-3 and PdBD were cloned into plasmid
pPA195 and pPA180, respectively, and transformed into
Lactococcus lactis PA1001. The overexpression of BVH-3
and PdBD was induced by nisin, essentially as described
previously [33]. The purity of the recombinant proteins
was determined by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). The amino acid sequence of
the proteins was confirmed with mass spectrometry (Ultraflex
MALDI-ToF, Bruker Daltonics).
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Coupling methods
To quantify antibodies directed against the 17 S. pneumoniae
proteins simultaneously, the bead-based flow cytometry
technique (xMAP®, Luminex Corporation) was applied.
The purified proteins were coupled to fluorescent SeroMAP
beads. The coupling procedure was performed as described
elsewhere [34, 35]. In each experiment, control beads were
included to determine non-specific binding. For control
beads, the coupling procedure was followed, except that no
S. pneumoniae protein was added. In case of non-specific
binding, the median fluorescence intensity (MFI) values
were subtracted from the antigen-specific results. As a
negative control, PBS-BN was included. Human pooled
serum was used as a standard.
Multiplex S. pneumoniae antibody assay
The multiplex assay (serum incubated with the different
fluorescence-coloured antigen-coupled beads mixed in one
well) was validated by comparing the MFI values for HPS
obtained with this multiplex assay with the results for HPS
obtained with singleplex assays (serum incubated with
individual single-colour antigen-coupled beads in separate
wells). After validation, the different antigen-coupled
microspheres were mixed to a working concentration of
4,000 beads per colour per well. The procedure used was
the same as that described elsewhere [34–36]. To optimise
dilutions, the serum samples of children were diluted 1:25,
1:50 and 1:100 in PBS-BN. The secondary antibodies were
diluted 1:50, 1:100 and 1:200 in PBS-BN. Checkerboard
titrations were performed. Considering the results of the
MFI values and the amounts of serum and secondary
antibody needed, optimal serum dilutions were 1:100 for
the measurement of IgG and 1:50 for the measurement of
antigen-specific IgA and IgM. The optimal secondary
antibody dilutions were 1:200 for IgG and 1:100 for IgA
and IgM. Measurements were performed on the Luminex 100
instrument (BMD) using Luminex IS software (version 2.2).
Tests were performed in duplicate, and the MFI values,
reflecting semi-quantitative antibody levels, were averaged.
Anti-pneumococcal antibodies
The multiplexed immunoassay was used to compare
differences in anti-pneumococcal antibodies in the serum
samples obtained from 54 children under the age of 5 years
with clinical suspicion of pneumonia (n=26) or meningitis
(n=28). Half of these children suffered from pneumonia/
meningitis caused by S. pneumoniae and the other half
suffered from pneumonia/meningitis caused by a bacterial
species other than S. pneumoniae. The serum samples were
stored at −80°C until use. The research protocol was
approved by the Research Review and Research Ethical
Committee of ICDDR,B and written informed consent from
the parents was obtained.
Statistical analysis
The Mann–Whitney U-test was used to compare differences
in the anti-pneumococcal antibody levels. Differences were
considered to be statistically significant when the two-sided
p-values were <0.05.
Results and discussion
Validation of the multiplex assay and reproducibility
The MFI values obtained for HPS with the multiplex assay
were between 82% and 111% (median 94%) of those
obtained with the singleplex assays. Therefore, it was
considered to be legitimate to use the multiplex assay.
Serum incubated with control beads resulted in median MFI
values for IgG, IgA and IgM of 77 (range, 21–7,210), 92
(range, 15–11,549) and 1,282 (range, 171–7966), respec-
tively. This indicates that there was quite a variable level of
non-specific binding that was consistently subtracted from
the antigen-specific results. The negative control (PBS-BN)
incubated with protein-coupled beads resulted in low MFI
values (<10). Inter-assay variation was calculated from the
MFI values obtained from serum samples (n=54) run in
two separate assays and averaged per protein and antibody
isotype. For IgG, the median coefficient of variation (CV)
was 5%, range 2% (PsaA) to 9% (SlrA). For IgA, the
median CV was 7%, range 3% (PspC and PsaA) to 14%
(SlrA). For IgM, the median CV was 13%, range 11%
(SP1633) to 15% (PspC, PpmA and PspA). Earlier studies
found equal CVs for inter-assay variation using other types
of antigens [20, 34, 37]. Therefore, this new multiplexed
anti-pneumococcal immunoassay is considered to be
reproducible from experiment to experiment.
Anti-pneumococcal antibodies
Anti-pneumococcal antibody levels showed extensive inter-
individual variability (Fig. 1), probably due to the variable
number of previous encounters with different S. pneumoniae
strains (colonisation, subclinical infection), as well as inter-
individual differences in the ability to mount a humoral
immune response. The levels of IgM were not significantly
different between children suffering from a pneumonia/
meningitis caused by S. pneumoniae or by a different
bacterial species. The levels of IgG directed against NanA
and the levels of IgA directed against Hyl and PpmA were
higher in children suffering from a pneumonia caused by S.
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pneumoniae than in children suffering from a pneumonia
caused by other bacterial pathogens (p<0.05, Fig. 1a). In
contrast, significantly higher levels of antibodies directed
against IgA1-protease were detected in the serum samples of
patients suffering from a non-S. pneumoniae pneumonia.
This might be explained by the fact that IgA1-protease is
also present in Haemophilus influenzae [38], another
frequent cause of pneumonia in non-vaccinated children. In
meningitis patients, the levels of IgG directed against PspC,
PdBD and PLY were significantly higher in children
suffering from meningitis caused by a bacterial pathogen
other than S. pneumoniae (p<0.05, Fig. 1b). Furthermore,
the levels of IgA directed to PdBD, PLY, SP0189 and
SP1003 were higher in this group (p<0.05). We speculate
that the lower S. pneumoniae antibody levels in the children
suffering from S. pneumoniae meningitis might be due to the
consumption of antibodies. However, such data can be
obscured by the fact that we do not know the exact patient
delay (time between the onset of disease and the arrival in
the hospital and the collection of serum). Furthermore, the
sera from children of different ages were included.
In conclusion, using our novel non-polysaccharide-based
high-throughput immunological test, we were able to deter-
mine the level of antibodies to 17 pneumococcal proteins
simultaneously in small-volume serum samples. The require-
ment for small sample volumes only is a great advantage as
compared to enzyme-linked immunosorbent assay (ELISA),
especially when limited amounts of samples are available,
which is usually the case in young children. Novel antigens
can be easily included and combinations of protein and
polysaccharide antigens may help in profiling the complete
immune response of both patients and healthy individuals to a
common opportunistic pathogen, which is especially relevant
in children in developing countries.
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